AU696373B2 - Cancer treatment and metastasis prevention - Google Patents

Cancer treatment and metastasis prevention Download PDF

Info

Publication number
AU696373B2
AU696373B2 AU24023/95A AU2402395A AU696373B2 AU 696373 B2 AU696373 B2 AU 696373B2 AU 24023/95 A AU24023/95 A AU 24023/95A AU 2402395 A AU2402395 A AU 2402395A AU 696373 B2 AU696373 B2 AU 696373B2
Authority
AU
Australia
Prior art keywords
hyaluronic acid
vitamin
sodium hyaluronate
sodium
voltarol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU24023/95A
Other languages
English (en)
Other versions
AU2402395A (en
Inventor
Samuel Simon Asculai
Rudolf Edgar Falk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alchemia Oncology Pty Ltd
Original Assignee
Hyal Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharmaceutical Corp filed Critical Hyal Pharmaceutical Corp
Publication of AU2402395A publication Critical patent/AU2402395A/en
Assigned to HYAL PHARMACEUTICAL CORPORATION reassignment HYAL PHARMACEUTICAL CORPORATION Alteration of Name(s) of Applicant(s) under S113 Assignors: NORPHARMCO INC.
Application granted granted Critical
Publication of AU696373B2 publication Critical patent/AU696373B2/en
Assigned to JAGOTEC AG reassignment JAGOTEC AG Alteration of Name(s) in Register under S187 Assignors: HYAL PHARMACEUTICAL CORPORATION
Assigned to MEDITECH RESEARCH LIMITED reassignment MEDITECH RESEARCH LIMITED Alteration of Name(s) in Register under S187 Assignors: JAGOTEC AG
Assigned to ALCHEMIA ONCOLOGY LIMITED reassignment ALCHEMIA ONCOLOGY LIMITED Request to Amend Deed and Register Assignors: MEDITECH RESEARCH LIMITED
Assigned to ALCHEMIA ONCOLOGY PTY LIMITED reassignment ALCHEMIA ONCOLOGY PTY LIMITED Request to Amend Deed and Register Assignors: ALCHEMIA ONCOLOGY LIMITED
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU24023/95A 1994-04-29 1995-04-28 Cancer treatment and metastasis prevention Expired AU696373B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002122519A CA2122519C (fr) 1994-04-29 1994-04-29 Traitement du cancer et prevention des metastases
CA2122519 1994-04-29
PCT/CA1995/000259 WO1995030423A2 (fr) 1991-07-03 1995-04-28 Traitement du cancer et prevention des metastases

Publications (2)

Publication Number Publication Date
AU2402395A AU2402395A (en) 1995-11-29
AU696373B2 true AU696373B2 (en) 1998-09-10

Family

ID=4153495

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24023/95A Expired AU696373B2 (en) 1994-04-29 1995-04-28 Cancer treatment and metastasis prevention

Country Status (11)

Country Link
EP (1) EP0760667A1 (fr)
JP (1) JPH09512797A (fr)
KR (1) KR970702728A (fr)
CN (1) CN1151118A (fr)
AU (1) AU696373B2 (fr)
CA (1) CA2122519C (fr)
CZ (1) CZ308996A3 (fr)
HU (1) HUT75868A (fr)
RU (1) RU2162327C2 (fr)
SK (1) SK137996A3 (fr)
WO (1) WO1995030423A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
CA2175282A1 (fr) * 1996-04-29 1997-10-30 Rudolf Edgar Falk Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
CA2208924A1 (fr) * 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Utilisation reduite de paclitaxel grace a l'hyaluronan
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US7151099B2 (en) 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
CZ299095B6 (cs) * 1997-08-29 2008-04-23 Biogen Idec Ma Inc. Bunecný systém pro lécení rakoviny obsahující bunku savce a virový vektor s genem kódujícím proteininterferon-beta, farmaceutický prípravek obsahující takový bunecný systém a zpusob jeho výroby
CA2370003C (fr) * 1999-01-13 2008-08-19 Tracey Brown Composition visant a accroitre l'efficacite de medicaments et methodes afferentes
WO2000048597A1 (fr) 1999-02-18 2000-08-24 Novartis Ag Utilisation systemique d'antagonistes du recepteur 5-ht3 contre des processus inflammatoires rhumatismaux
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
AU784356B2 (en) 1999-12-28 2006-03-16 Bioniche Urology Ip Inc. Hyaluronic acid in the treatment of cancer
US6641571B2 (en) 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
JP5027387B2 (ja) * 2002-07-01 2012-09-19 タフツ・ユニバーシティ ヒアルロナンオリゴマーにより多剤耐性を阻害する方法及び組成物
US20060003027A1 (en) * 2004-06-30 2006-01-05 Zhou James H Composition and method for reducing side effects of indole-3-carbinol and derivatives
CA2616607C (fr) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Protocoles therapeutiques utilisant hyaluronan
JP5627181B2 (ja) 2005-09-07 2014-11-19 アルケミア オンコロジー ピーティーワイ リミテッド ヒアルロナンおよび治療用抗体を含む治療用組成物ならびに治療方法
US10219997B2 (en) 2006-09-22 2019-03-05 Kochi University Radiation sensitizer or anti-cancer chemotherapy sensitizer
KR100856114B1 (ko) * 2008-04-18 2008-09-02 강지민 리모컨을 이용한 텔레비전 음향과 데이터 송수신방법
EP2365815B1 (fr) * 2008-11-14 2019-09-18 Histogen, Inc. Compositions de matrice extracellulaire pour le traitement du cancer
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
RU2586043C1 (ru) * 2014-11-12 2016-06-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" Способ профилактики и лечения осложнений при лучевой терапии рака кожи
RU2723883C2 (ru) * 2018-07-17 2020-06-18 Николай Васильевич Цугленок Способ инициации гибели опухолевых клеток аскорбиновой и гидрозидом 3-аминофталевой кислотами и ВЧ- и СВЧ-энергией волнового излучения

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (fr) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
CA2061566C (fr) * 1992-02-20 2002-07-09 Rudolf E. Falk Traitement des maladies par l'acide hyaluronique et des ains
CA2061703C (fr) * 1992-02-20 2002-07-02 Rudolf E. Falk Compositions renfermant de l'acide hyaluronique
CA2097892A1 (fr) * 1993-06-07 1994-12-07 Rudolf Edgar Falk Prevention du cancer et lutte contre le cancer

Also Published As

Publication number Publication date
JPH09512797A (ja) 1997-12-22
AU2402395A (en) 1995-11-29
KR970702728A (ko) 1997-06-10
CA2122519A1 (fr) 1995-10-30
EP0760667A1 (fr) 1997-03-12
WO1995030423A2 (fr) 1995-11-16
HUT75868A (en) 1997-05-28
RU2162327C2 (ru) 2001-01-27
CA2122519C (fr) 2001-02-20
CZ308996A3 (cs) 1998-01-14
CN1151118A (zh) 1997-06-04
SK137996A3 (en) 1998-08-05
HU9602965D0 (en) 1997-01-28
WO1995030423A3 (fr) 1995-12-21

Similar Documents

Publication Publication Date Title
AU696373B2 (en) Cancer treatment and metastasis prevention
Eisenberger et al. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck.
JP3256761B2 (ja) 症状及び疾病の治療
Feun et al. Intracarotid infusion of cis‐diamminedichloroplatinum in the treatment of recurrent malignant brain tumors
Riordan et al. Intravenous ascorbic acid: protocol for its application and use
PT1478355E (pt) Composições antitumorais contendo derivados de taxano.
OA10698A (en) Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof.
Kardinal et al. Combined doxorubicin and alpha‐interferon therapy of advanced hepatocellular carcinoma
WO1997021444A9 (fr) Activateur de production endogene de facteur hemopoietique et de cytokine, et procedes d'utilisation
Morise et al. Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases
Jones et al. Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer.
Frasci et al. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study
Seiter et al. Uridine allows dose escalation of 5‐fluorouracil when given with N‐phosphonacetyl‐L‐Aspartate, methotrexate, and leucovorin
Legha et al. Phase I study of spirogermanium given daily.
Chen et al. Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas
Markman Intraperitoneal chemotherapy in the treatment of ovarian cancer
Sutton Ifosfamide and mesna in epithelial ovarian carcinoma
Schilsky et al. Phase I Clinical Evaluation of Cytarabine and Cisplatin in Patients With Advanced Cancer¹
Prasad et al. Vitamin K deficiency with hemorrhage after kidney and combined kidney–pancreas transplantation
Dimery et al. Sequential methotrexate, 5-fluorouracil, and cisplatin in the treatment of recurrent squamous-cell carcinoma of the head and neck: failure of hypertonic saline to reduce the nephrotoxicity of cisplatin.
Saltz et al. A phase I trial of cisplatin in hypertonic saline and escalating doses of 5‐fluorouracil by continuous intravenous infusion in patients with advanced malignancies
Neidhart et al. Phase I Trial of Teroxirone¹, 2
Whitehead et al. Phase II Trial of CI-980 in Patients with Disseminated Malignant Melanoma and no Prior Chemotherapy–A Southwest Oncology Group Study
JP2009046450A (ja) 抗がん剤へのヒアルロン酸添加
Liu et al. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: JAGOTEC AG

Free format text: FORMER OWNER WAS: HYAL PHARMACEUTICAL CORPORATION

PC Assignment registered

Owner name: MEDITECH RESEARCH LIMITED

Free format text: FORMER OWNER WAS: JAGOTEC AG